

News release

Kyowa Kirin Announces Discontinuation for Developing KW-6356

Tokyo, Japan, 15 July 2022 -- Kyowa Kirin Co., Ltd. (TSE:4151, President and CEO: Masashi Miyamoto, "Kyowa Kirin") announces today the discontinuation of its clinical development program for KW-6356, an adenosine A_{2A} receptor antagonist/inverse agonist with applications in neurology. The novel compound was discovered by Kyowa Kirin.

Kyowa Kirin conducted Phase 2 clinical studies of KW-6356 in Japan for Parkinson's disease and found it to be potentially effective in relieving motor and non-motor symptoms both as monotherapy and in combination with levodopa-containing therapy. However, the company decided to discontinue KW-6356's development after a thorough evaluation of the global regulatory landscape, development hurdles, and timelines for potential market entry.

The Kyowa Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.